TBX1 and malignant colon neoplasm: Furthermore, a phase I trial (NCT02179515) was performed to test the safety and tolerability of a modified vaccinia Ankara (MVA)-based vaccine modified to express brachyury and T-cell costimulatory molecules (MVA-Brachyury-TRICOM) in advanced patients including colon cancer patients.